LifeSci Capital Rates Veradermics (MANE) buy, $135 Price Target
LifeSci Capital maintains its buy rating on MANE, setting a $135 price target, a 40.23% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
LifeSci Capital rated Veradermics, Incorporated ($MANE) "buy" with a $135 price target on June 16, 2026.
Since the rating, $MANE is up 13.9% after 1 week, up 16.4% after 1 month and up 19.6% to date (from the $90.95 close on Jun 16, 2026).
MANE
Veradermics, Incorporated
Key Points
- LifeSci Capital reiterated its buy rating on MANE with a $135 price target on June 16, 2026.
- LifeSci Capital's $135 price target implies 40.23% upside from Veradermics, Incorporated's ($MANE) current $96.27 share price.
- MANE shares are trading around $96.27, with several analysts maintaining a positive outlook.
- Institutional investors like Ameriprise Financial and Jennison Associates hold significant positions in MANE.
Get $MANE trade alerts by text
We text you when insiders, Congress or big funds trade $MANE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Veradermics, Incorporated alert may contain errors. Disclosures
On June 16, 2026, LifeSci Capital reiterated its buy rating on MANE, setting a price target of $135. The shares are currently trading at about $96.27.
Other Institutional Activity in MANE
Ameriprise Financial Inc holds 514,035 shares of MANE, valued at approximately $32.46 million. Jennison Associates LLC has 141,781 shares, worth around $8.95 million. Similarly, Emerald Advisers, LLC controls 132,536 shares, valued at about $8.37 million, while Emerald Mutual Fund Advisers Trust holds 109,283 shares, valued at $6.90 million. Seven Grand Managers, LLC and Bamco Inc /NY/ have smaller stakes, with 74,750 and 59,668 shares, valued at $4.72 million and $3.77 million, respectively.
Analysts Set New Price Targets
On June 16, 2026, LifeSci Capital reiterated its buy rating on MANE with a $135 price target. Earlier, on June 2, 2026, Needham initiated coverage with a buy rating and a $136 target. Citigroup maintained its buy rating with a $135 target on May 18, 2026. Leerink Partners maintained a buy rating with a $90 target on April 22, 2026.
About MANE
MANE is involved in diverse sectors, focusing on providing innovative solutions across its industry. The company is committed to delivering high-quality products and services to its customers worldwide. As a dynamic player, MANE continues to expand its footprint in various markets, driven by a strong leadership team and a dedicated workforce.
Bottom Line
LifeSci Capital's reiteration of a buy rating with a $135 target reflects ongoing confidence in MANE's potential. Investors often track such analyst updates to gauge market sentiment. It's important to note that analyst ratings are forward-looking and may not reflect current market conditions.
$MANE price target
Veradermics, Incorporated daily closes and this analyst's $135 target. Not advice.
Related Filing Alerts
Source: LifeSci Capital's rating change on $MANE (Jun 16, 2026). Written by software, not financial advice. How we make alerts